Given that decreased levels of cobalamin have been reported in the frontal cortex in schizophrenia and autism compared with controls33, the effect of ABCD4 point mutations in the metabolic processes of cobalamin in brains should be investigated in future studies. The gene discussed is ABCD4; the disease is schizophrenia.